Bristol Myers Squibb stock holds near $67.86 after Cellares exit
Published on 08/27/2026 at 09:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (US0897961004) traded at $67.86 on August 26, 2026, with a market capitalization of $138.62 billion and a 52-week range of $42.52 to $68.64. The move comes as investors weigh a Reuters-linked update that the company ended its Cellares partnership and the latest reported quarter, which showed $2.04 in EPS on $12.97 billion in revenue.
Cellares exit resets one manufacturing tie-up
A Reuters-linked health summary said Bristol Myers Squibb ended its partnership with cell therapy startup Cellares after deciding the Cell Shuttle platform could not meet the requirements to make Breyanzi at commercial scale. The same summary put the decision in the context of broader drug-pricing attention across the sector, with Washington planning new pricing deals with midsized biotech companies.
The manufacturing call matters because the company has been using capital and partnerships to support cell therapy scale-up, while the market is still valuing the shares at 14.95 times earnings and 0.17 times growth, based on the latest market snapshot.
July 30 numbers still anchor the story
The most recent reported quarter delivered $2.04 in EPS, which topped consensus by $0.44, and revenue rose 5.7% year over year to $12.97 billion versus $11.74 billion expected. FY 2026 guidance was set at $6.75 to $7.00 per share, while analysts in the same market snapshot were looking for $6.95 per share for the current fiscal year.
That gap between guidance and consensus is small but important. It leaves Bristol Myers Squibb with a current earnings bar that is still manageable even after the stock has advanced to within $0.78 of its 52-week high.
What investors are watching next
For investors, the next test is whether the shares can hold a premium near the high end of the 52-week band while the company executes on guidance and absorbs any operational changes from the Cellares decision. Institutional ownership was listed at 76.41%, and a recent dividend of $0.63 per share still implies a 3.7% annualized yield.
Breyanzi remains a key product
Breyanzi is the company's personalized CAR-T therapy for blood cancers, and it remains central to Bristol Myers Squibb's cell-therapy portfolio after the manufacturing split with Cellares. The product's commercial scale and supply chain still matter because they affect how quickly the company can convert clinical and regulatory progress into revenue.
Shares near the high
Bristol Myers Squibb stock was last quoted at $67.86 on August 26, 2026, with a market cap of $138.62 billion and a 52-week high of $68.64. The shares are priced close to that ceiling while the company works through its latest operational and financial update cycle.
Fact box
Company: Bristol Myers Squibb Company
ISIN: US0897961004
Ticker: BMY
Exchange: NYSE
Sector / Industry: Healthcare / Biotechnology
Index membership: S&P 500
Market cap: $138.62 billion
Price: $67.86 as of August 26, 2026
Next earnings date: November 2026
More on Bristol Myers Squibb stock
The company's product mix still leans on oncology, hematology, immunology, cardiovascular disease and specialty medicines, which keeps execution on large marketed therapies and late-stage assets important for the stock's valuation.
